



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

December 28, 2017

Brian Lian, Ph.D.  
President and Chief Executive Officer  
Viking Therapeutics, Inc.  
12340 El Camino Real, Suite 250  
San Diego, CA 92130

**Re: Viking Therapeutics, Inc.**  
**Registration Statement on Form S-1**  
**Filed December 20, 2017**  
**File No. 333-222202**

Dear Dr. Lian:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Jeffrey Gabor at 202-551-2544 with any questions.

Division of Corporation Finance  
Office of Healthcare & Insurance

cc: Jeff Hartlin